SEP 29, 2020 9:00 AM PDT

Cycling Molecules into Drug Candidates

SPONSORED BY: Charles River

Statistics show that just 1 in 5,000 drug candidates ever makes it from the lab to the pharmacy. In a process that can take as long as 10 years, novel drugs require more time and money with every stage of development. Thus, killing a failure early is as valuable as pushing through a winner.

In early discovery, both of these tasks fall to the medicinal chemists, biologists, and pharmaceutical scientists. “It’s iterative,” says Omar Aziz, Senior Director of Biology at Charles River’s Harlow, UK site. “The main idea is we build chemistry, build better molecules that are more efficacious, that are more stable, that actually have greater access to target tissues and organs.”

Individually, Omar is but one pillar of a trifecta of talent whose purpose is to create better molecules. Directing the team’s early discovery chemistry operations, Karen Williams guides the process of identifying new compounds. Russell Scammell leads the group’s efforts in pharmaceutical formulation chemistry and analytics. On a typical day at the Harlow site, compounds ping back and forth between the three groups in a concentrated their quest to develop a lead candidate.

We might not consider where that heart pill, diabetes medicine, or chemo drug comes from, but Omar, Russ and Karen think about it all the time. Motivated to find that rare molecule among thousands that will make a difference to patients with heart disease, diabetes or cancer, they embrace the challenges that demand their collective creative problem solving. According to Omar, developing a full understanding of a compound is hugely important, as there is always room for improvement. He adds, “I don’t believe there’s a single drug on the market that couldn’t be improved in some area or aspect of its properties.” 

The quest for a candidate compound begins with target validation, or the search for a “druggable” target that can be affected by a compound. From there, screening assays determine which compounds interact with the target in a process called hit ID. After collecting as much data as possible, a promising compound moves to physiological assays that determine whether it has the desired effects in vivo. “The end result is a drug that’s in the market, that is hitting the target, and this can be used on, on a day-to-day basis across a range of activities,” says Russ. Over numerous iterations, a drug may pass back and forth through each phase as it is either validated, refined, or failed. At each step of the way Karen, Russ, Omar, and their colleagues share successes and setbacks to keep a drug moving forward as quickly and cost-effectively as possible without sacrificing safety. Their appreciation for each other’s contributions to the final product is evident. 

“I always joke about chemists being the most optimistic people in the world, because it doesn’t matter how many compounds they’ve made that just have not met the grade, they’re still excited about the next one,” said Omar. “Whereas biologists, I would probably say are a bit more conservative, maybe a bit more pessimistic in their approach. They’re going to look at it and think, it’s just another compound. Is this going to be different from the last one? So, there’s a lot of banter that goes on and I think it’s taken in good humor with all parties involved,” says Omar. 

In the end, the three agree that their work benefits from their close collaboration and their camaraderie. Working through setbacks and celebrating victories may not get covered in school, but those moments can make a job into a career and a passion.

Meet our scientists and learn more  

About the Sponsor
  • At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. The drug research and development process is highly complex, yet essential for delivering safe and effective therapies to patients.
You May Also Like
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
NOV 11, 2020
Health & Medicine
A smart path for novel biologics
NOV 11, 2020
A smart path for novel biologics
Introduction  Cell culture is at the heart of the production process for many biopharmaceuticals, but finding the o ...
OCT 22, 2020
Neuroscience
Psychedelic Experiences Reduce Narcissistic Personality Traits
OCT 22, 2020
Psychedelic Experiences Reduce Narcissistic Personality Traits
Researchers from the UK have found that psychedelic drugs can positively affect narcissistic personality traits- by redu ...
OCT 01, 2020
Drug Discovery & Development
Antidepressants Treats Lazy Eye
OCT 01, 2020
Antidepressants Treats Lazy Eye
A study published in Current Biology revealed how a therapeutic used as an antidepressant and for managing pain could tr ...
NOV 06, 2020
Immunology
The Coronavirus Is No Match Against Sybody 23
NOV 06, 2020
The Coronavirus Is No Match Against Sybody 23
The virus that causes COVID-19, SARS-CoV-2, uses its spike protein to gain access to cells, by binding to the ACE2 recep ...
NOV 15, 2020
Drug Discovery & Development
Antidepressant May Prevent Worsening of COVID-19 Infections
NOV 15, 2020
Antidepressant May Prevent Worsening of COVID-19 Infections
  Researchers from the Washington University School of Medicine in St. Louis have found that fluvoxamine, a common ...
Loading Comments...